Hledat klinickou studii
11 Výsledků
Studie přijímající pacienty
= 
; Probíhající studie = 
; Ukončená studie = 
; Financováno členem konsorcia IRDiRC = 
; Člen ERN = 
Národní klinické studie
RAKOUSKO
WIEN
ADDRESS: NOT PROVIDED - AT
A Phase 2 Study of TAS-117 in Patients With Advanced Solid Tumors Harboring Germline PTEN Inactivating Mutations - AT
Institution: Information not provided - AT
BELGIE
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
VASE: Etude multicentrique de phase III visant à évaluer l'efficacité et la sécurité d'emploi du sirolimus dans le traitement des malformations vasculaires réfractaires aux soins standards - BE
Cliniques universitaires Saint-Luc - UCLouvain
Centre des Malformations Vasculaires
FRANCIE
NORMANDIE
CAEN
NĚMECKO
Baden-Württemberg
FREIBURG
SIPA-SOS: Offene Phase II Studie mit Sirolismus in Patienten mit segmentalem Überwuchssyndrom
Zentrum für Kinder- und Jugendmedizin Freiburg
Klinik für Pädiatrische Hämatologie und Onkologie
SPOJENÉ STÁTY
Washington
ADDRESS: NOT PROVIDED - US
A Randomized Double-Blind Controlled Trial of Everolimus in Children and Adolescents With PTEN Mutations (RAD001XUS257T)
Institution: Information not provided - US
NIZOZEMSKO
Noord-Holland
AMSTERDAM
The Drug Rediscovery Protocol (DRUP trial): A Dutch National Study on behalf of the Center for Personalized Cancer Treatment (CPCT) to Facilitate Patient Access to Commercially Available, Targeted Anti-cancer Drugs to determine the Potential Efficacy in Treatment of Advanced Cancers with a Known Molecular Profile (Phase II)
Het Nederlands Kanker Instituut - Antoni van Leeuwenhoek Ziekenhuis
Afdeling Maag-Darm-Leveroncologie
BELGIE
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
STEP: Programme d'extension à long terme du Sorafénib - BE
Cliniques universitaires Saint-Luc - UCLouvain
Pneumologie_Oncologie thoracique
ITÁLIE
EMILIA ROMAGNA
ADDRESS: NOT PROVIDED - IT
Studio in aperto di fase I/II per valutare la sicurezza, la tollerabilità e l'efficacia preliminare di durvalumab in monoterapia o in combinazione con tremelimumab in pazienti pediatrici con tumori solidi avanzati e neoplasie ematologiche
Institution: Information not provided - IT
ITÁLIE
LAZIO
ROMA
Studio in aperto, a braccio singolo, di fase 1/2 che valuta la sicurezza e l'efficacia di Ponatinib per il trattamento delle leucemie ricorrenti o refrattarie o dei tumori solidi in pazienti pediatrici
IRCCS Ospedale Pediatrico Bambino Gesù - SEDE GIANICOLO
U.O. di Oncoematologia
SPOJENÉ STÁTY
Washington
ADDRESS: NOT PROVIDED - US
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Institution: Information not provided - US
Nadnárodní klinické studie
BELGIE
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS